This study investigates the safety, tolerability, and pharmacokinetics of an investigational medication in patients with select advanced solid tumors, such as metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer. The purpose of this study is to find the optimal dose of the investigational medication for these patients.
Participants will undergo a two-part study process. Phase 1a involves dose escalation to evaluate the initial safety and tolerability of the investigational medication. Phase 1b will further assess safety and tolerability, as well as the preliminary effectiveness of the investigational medication in patients with previously treated metastatic castration-resistant prostate cancer.
- Who can participate: Participants must have select advanced solid tumors, including metastatic castration-resistant prostate cancer, gastric cancer, or non-small cell lung cancer. They should have a performance status of 0-1 (Phase 1a) or 0-2 (Phase 1b) and adequate organ function.
- Study details: Participants will receive the investigational medication and be monitored for safety, tolerability, and effectiveness. The study involves dose escalation and expansion phases to determine the best dose.
How understandable was the trial content above?
Hard to understand
Easy to understand
